Immunomodulation is increasingly being recognised as a part of mental diseases. Here, we examined if levels of immunological protein markers altered with depression, age or by the inhibitory neurotransmitter gamma-aminobutyric acid (GABA).
Introduction
Neurotransmitter signaling is well studied in the nervous system, where GABA is the main inhibitory transmitter [1] . Compelling evidence demonstrates that neurotransmitter signaling also takes place in the immune system [2] [3] [4] [5] [6] [7] . The fact that a cross-talk occurs between the immune-and the nervous systems is not surprising. It may be required for normal brain functions and is probably essential for coordinated stress, emotional and behavioural responses [8] . Dysregulation of the immune system has furthermore been reported to be associated with psychiatric disorders, such as depression [8] . Pro-inflammatory cytokines can induce sickness behaviour that resembles major depressive disorder (MDD) and interferonalpha (INF-α) treatment induces MDD in about 25% of cases, suggesting causal mechanisms [9, 10] . Pro-inflammatory markers such as IL-6, IL-1β, IFN-α, TNF-α and MCP-1/CCL2 are increased in the blood and cerebrospinal fluid (CSF) from patients with mood disorders compared to healthy controls, when assessed at baseline and also after exposure to stressors [11] [12] [13] . Inflammatory markers such as IL-6 and CRP are consistently found to be elevated in depression although the size of the effect is relatively small [14, 15] . Emerging evidence also indicates that antidepressants have immunomodulating effects and that inflammatory-and pro-inflammatory cytokines undermine the treatment response to conventional antidepressants [16] [17] [18] [19] [20] [21] . Understanding the immunological changes in depression is important, as immunomodulation may be a possible therapy for some patients with depression.
In the brain, GABA is produced from glutamate in neuronal cells by the enzyme glutamic acid decarboxylase (GAD) [22] . Central nervous system (CNS) interstitial GABA and the human plasma GABA concentrations are expected to be in the submicromolar range [23] [24] [25] [26] , though the origin of GABA in blood is still being explored. Recently identified drainage system of the brain, the glymphatic system, indicates the brain as a significant source of the GABA present in blood [27] . The expression of GABA receptors subunits and activation of functional GABA A receptors has been recorded in immune cells such as PBMCs, T cells, monocytes, dendritic cells and macrophages [7, 28] . Recently, we demonstrated that GABA inhibits secretion of a variety of inflammatory protein markers from PBMCs and T cells from healthy individuals and type 1 diabetes patients [7] . Nevertheless, the effects of GABA on secretion of cytokines/immunological markers from immune cells is still relatively unexplored.
Here, we analyzed the immunological markers in plasma, from CBD and patients with a major depressive episode, and how they altered with age. We further studied expression of the GABA signaling system components and effects of GABA treatment on the inflammatory markers profile of stimulated PBMCs from the patients. The results highlight augmented levels of immunological markers and the neurotransmitter GABA in the plasma of patients, together with altered GABA signaling in PBMCs from patients. The results are consistent with immunomodulatory effects of GABA during depression. Furthermore, the level of a number of inflammatory markers correlated with age for both groups.
Results
Demographic data for the individuals (CBD:26; P:25) that participated in the study are shown in Table 1 and Supplementary Table 2 . In total, 38 patients that met the criteria were selected for this study. Of these 38 patients, 7 patients chose not participate, while 6 individuals were found unable to provide informed consent due to cognitive symptoms. Thus, 25 patients were included in the study ( Table 1 ). All the patients met the DSM IV criteria for current moderate to severe depressive episode and either major depressive disorder or bipolar disorder. They were all undergoing treatment of depression at the Department of General Psychiatry at Uppsala University Hospital, Sweden, at the time the samples were obtained. Eleven of the patients were prescribed benzodiazepines or "Z-drugs", while three of the patients had both. None of the patients had a documented history of alcohol addiction or abuse disorder and none had consumed alcohol during the past week prior to the sampling. Two patients had received ECT during the past three months but none during the past month. Five patients have previously received ECT during their lifetime. Two patients had neurodevelopmental disorders but the physician evaluated them to be capable of judgment in giving consent. In three cases, the MINI interview could not be performed due to cognitive symptoms, one case developed psychotic symptoms with delusions and severe disorganized thinking 24 hours after giving consent, another patient presented severe concentrating difficulties and the last one did not consent to the interview due to fatigue. Diagnosis in these cases was made based on clinical records.
Inflammatory markers in plasma from patients and control donors
Immune cells release a large number of small proteins, collectively called inflammatory markers, which may have a protective function or act as pro-inflammatory molecules. We investigated whether the types of inflammatory markers in plasma differed between CBD and the patients. We measured the plasma levels of 92 inflammatory markers that are most commonly associated with inflammation using an Olink inflammation panel analyzed with multiplex PEA (Table S3 ) (http://www.olink.com/products/inflammation/#).
The technology uses paired antibodies for the different inflammatory markers such as cytokines, growth factors, mitogens, chemotactic, soluble receptors and other proinflammatory molecules that allows comparison of the levels of the same marker in samples from e.g. CBD and the patients. However, the assay format does not support comparison of the absolute levels of one marker to another as the affinities of the antibodies for their cognate targets may vary. In plasma from both CBD and patient groups, 67 inflammatory markers out of 92 analyzed proteins were detectable with values above LOD ( Fig. 1A ; Table S4 ).
Importantly, 13 inflammatory markers were significantly higher in plasma from the patients as compared to plasma from CBD ( Fig. 1B) .
Effects of age on levels of inflammatory markers in plasma
Since the patients varied in age, we examined if there were any correlations between age and the level of the inflammatory markers in plasma from the two groups. Ten inflammatory markers correlated with age in CBD ( Fig. 2A ; Table S5 ) and 21 in the patients ( Fig. 2B ; Table S5 ). Six inflammatory markers, IL-8, CXCL9, HGF, VEGF-A, OPG, MMP-1, correlated with age in both groups and thus may reflect normal aging processes rather than disease. Another three inflammatory markers, TGF-, EN-RAGE, OSM, only correlated with age in the patients but were also increased in plasma from patients as compared to CBD ( Fig.   1B and 2B). The strongest correlation with age in CBD was observed for CDCP1, a molecule with a role in immune cells migration and chemotaxis [29] [30] [31] , whereas in the patients, the strongest correlation was observed for CST5, a cysteine protease inhibitor which can also modulate gene transcription and protein expression [32, 33] . The inflammatory markers that varied with age can be grouped according to function and are shown in Figure 2C for the two groups. Inflammatory markers associated with activation of immune cell response and apoptosis were enhanced in plasma from the patients.
The GABA concentration in plasma and correlation of GABA or MADRS-S score with inflammatory markers
Since GABA is exclusively generated within the body, and is the main inhibitory neurotransmitter in the brain, we examined if the GABA concentration in plasma varied between CBD and the patients (Fig. 2D ). The results showed that the GABA concentration ranged from 253 to 824 nM in the two groups and revealed somewhat increased plasma GABA concentration in the patients, resulting in a significantly higher average plasma concentration (CBD: 58625 nM; PD: 68319 nM; p=0.003). In general, the GABA levels in plasma did not correlate with the inflammatory marker levels in plasma with the exception of LIF-R, ST1A1 in the CBD ( Fig. 2E , Table S5 ), neither with the age of the CBD or the patients nor with the MADRS-S score or the BMI of the patients. A posthoc analysis with ttest showed elevated levels of GABA in the patients with benzodiazepines and/or Z-drugs when compared to the remaining patients (t-value -2.354, p-value 0.037). Importantly, most of these patients were also treated with other medication with potential for influencing GABA. None of the markers correlated with BMI, whereas IL-18 was the only marker that correlated with the MADRS-S score of the patients ( Fig. 2F ; Table S5 , R-value -0.4832, pvalue 0.017). The GABA signaling system is altered in PBMCs from the patients GABA can activate two types of receptors in the plasma membrane of cells, the GABA A receptors that are chloride ion channels opened by GABA and the G-protein-coupled GABA B receptor [1, 34, 35] . The GABA A receptors are homo-or hetero-pentamers formed by a selection of subunits from 19 known isoforms (1-6, 1-3, 1-3, ,  , , 1-3) [35] . In contrast, the GABA B receptor is normally formed as a dimer of the two isoforms identified todate [34, 36] . The 2 subunit was the only GABA A subunit, which was expressed in PBMCs from most of the CBD and the patients (Fig. 3A , Table 2 ). The expression level was similar in both groups and could indicate the formation of homomeric 2 GABA A receptors in the cells.
Approximately 30-40% of the CBD also express the 1,  and  subunits, while the expression of these subunits was less frequent in the patients ( Table 2 ). Other GABA A subunits were expressed only infrequently in both groups ( Table 2 ). Only one GABA B subunit was expressed in both patients and CBD indicating that the traditional GABA B receptors may not be formed in the PBMCs ( Table 2 ).
The strength of GABA A receptor signaling depends, in part, on the chloride gradient across the cell membrane. We, therefore, examined if the expression of chloride transporters that regulate the intracellular chloride concentration differed between the CBD and the patients (Fig. 3B ). The NKCC1 transporter that transports chloride ions into the cells was significantly down-regulated in the PBMCs from the patients. The other three transporters, that move Clout of the cells, were also expressed in the majority of the samples but at similar levels in both groups.
GABA regulates release of inflammatory markers from stimulated PBMCs from the patients
Since the levels of inflammatory markers in plasma differed between the two groups and GABA has been reported to be immunomodulatory [7] , we examined if GABA affected release of inflammatory markers from the patients' PBMCs. The culture media of anti-CD3 stimulated PBMCs were assessed using the same Olink Inflammation protein panel composed of 92 inflammatory markers used for analysis of the plasma samples described above. We also examined if GABA at concentrations of 100 and 500 nM regulated secretion of specific inflammatory markers.
A total of 59 different inflammatory markers were detected in the culture media from both non-stimulated and the anti-CD3 stimulated PBMCs ( Fig. 4A ; Table S6 ), and additional nine markers (IL-2, IL-4, IL-5, IL-13, IL-2RB, IL-10RA, IL-15RA, PD-L1 and SLAM-F1) in the media from the stimulated cells. The majority of the inflammatory markers were secreted at a higher level in the stimulated PBMCs ( Fig. 4A ). Only VEGF-A was secreted at a significantly higher level in the resting state of the cells (Fig. 4A ). From the stimulated PBMCs, 51 inflammatory markers were the same as those identified in the plasma samples, while the remaining 17, including INF-, TNF- and IL-1, were not detected in the plasma samples. We further examined if treatment with GABA altered the release of inflammatory markers from the stimulated PBMCs as compared to non-treated PBMCs.
When 100 nM GABA was applied, there was a significant increase in secretion of 2 inflammatory markers, AXlN1 and TNFRSF9, and a decrease of another two, VEGF-A and IL-1 ( Fig. 4B , Table S7 ). With 500 nM GABA treatment, secretion of 4 inflammatory markers was significantly decreased from the stimulated PBMCs; CD244, IL-13, HGF and VEGF-A ( Fig. 4C ; Table S7 ). Of the inflammatory markers regulated by GABA, HGF and VEGF-A, increased with age in both, CBD and the patients (Fig. 1B) . Interestingly, of these seven inflammatory markers, only VEGF-A was modulated by both concentrations of GABA.
Discussion
This study examined peripheral inflammatory markers and the immunoregulatory effects of GABA and GABA signaling in PBMCs from patients with a major depressive episode (Fig. 5 ). The results identified thirteen inflammatory markers that were upregulated in plasma from the patients. Consistent with other studies, a number of inflammatory markers correlated with age for both CBD and the patients, but the most prominent age-associated marker differed for the two groups, being CDCP1 for the CBD and The inflammatory environment is thought to be altered in many psychiatric disorders [8, 9, 12] . The results in this report showed clear differences at the systemic level with the altered plasma concentrations of specific inflammatory markers in the patients ( Fig.   5 ). Inflammatory markers released from stimulated PBMCs from the patients identified additional markers that may be significant as auto-or paracrine signals. In the present study, the patients had increased levels of NGFs and neurotropin-3 (NT3) as compared to CBD and, notably, NGFs were not released from the simulated PBMCs. Low levels of NGFs have been implicated in the pathogenesis of depression and observed in patients with depressive disorders [37, 38] . -NGF and NT3 are the NGFs that increase viability, growth and development of neurons and may supress inflammation [39] . It is possible that the increase in NGFs levels in the patients is related to improvements in response to the antidepressants. This is in accordance with studies in animal models where increased expression/concentration levels of NT3 and NGF was observed in a number of brain regions and/or in serum in response to treatments with antidepressants [40] [41] [42] [43] . Interestingly, a recent study of inflammatory markers altered in plasma from patients with the autoimmune disease type 1 diabetic (T1D) or secreted by stimulated T1D PBMCs, identified many of the same inflammatory markers as in this study [7] . How small molecules from the brain reach the circulation is still being explored but they may diffuse by volume transmission from the brain to the blood [27] by the route of the active glymphatic system.
A number of studies have reported alteration in inflammatory markers with medical treatment. Recent meta-analysis studies have shown decreased plasma levels of IL-6, IL-10, IL-1, TNF-α, p11, IFN- and CCL2 after treatment with antidepressants, including SSRI and SNRI [18, [44] [45] [46] . Reduced mRNA expression of IL-6, IL-1b and MIF in leukocytes after treatment of patients with antidepressants, escitalopram or nortriptyline, has been reported [21] . Additionally, high levels of VEGF-A mRNA in whole blood from the patients with depression were reported although the VEGF protein levels in the plasma were not affected [47] . Further, increased IFN/IL-10 ratio and changes in CCL11 and IFN with antidepressant treatments has been reported [48, 49] but lithium augmentation of antidepressants had no effect on the inflammatory markers in MDD [50] .
Several inflammatory markers, that are often reported to be altered in patients with MDD, did not differ significantly between the patients in this study and CBD, e.g. IL-6.
A part of the explanation may potentially be that the antidepressant treatment normalized the levels of some of the inflammatory markers. However, MIP-1α (i.e. CCL3), CCL4 and CCL20, the macrophage-released pro-inflammatory molecules, were significantly elevated in the patients consistent with previous MDD reports [51, 52] . IL-18 was the only inflammatory marker that correlated with the MADRS-S score and is consistent with other studies of inflammatory markers and depression [53] [54] [55] [56] . Many inflammatory markers correlated with age in both CBD and the patients in concordance with previous studies [57] [58] [59] [60] . Our study corroborates that CDCP shows the strongest correlation with age in healthy individuals [59] whereas CST5 (cystatin D) with age in the patients. CST5 is an inhibitor of lysosomal and secreted cysteine proteases, but can also locate to the nucleus and modify gene transcription [33] . Interestingly, CST5 is an ultra-early biomarker of traumatic brain injury [32] .
The average plasma levels of GABA were increased in the patients as compared to age and sex matched CBD GABA levels, but there was, nevertheless, a narrow range of values and considerable overlap of sample GABA concentrations observed between the two groups. Circulating levels of GABA are much lower than those found in the synaptic cleft and instead comparable to levels activating high affinity extrasynaptic receptors, generating small amplitude but long lasting currents [1] . In previous studies where plasma GABA levels have been measured in samples from patients with psychiatric disorders and a control group, the results have varied [26, 61-66]. Since the majority of the patients in this study were being treated (medicines e.g. benzodiazepines, Li + , valproate or antipsychotic medication), it is possible that the difference observed in the GABA plasma concentration is related to the effect of the medications [65, 67] .
We and others have shown that immune cells can be regulated by GABA.
GABA can e.g. decrease proliferation of T cells, reduce inflammation in experimental autoimmune encephalomyelitis, decrease cytokine secretion from T cells and modulate mobility of infected dendritic cells [3-5, 7, 68, 69] . The PBMCs express genes for the diverse components of the GABA signaling system including the GABA A receptors and the chloride transporters [7] and respond to GABA by activating GABA A receptors channels [4, 7] . NKCC1, the transporter that maintains high intracellular chloride in the cells, was downregulated in PMBCs from the patients implying decreased strength of GABA signaling in the cells. The alteration in the chloride gradient across the plasma membrane is potentially partially compensated for by the somewhat increased GABA concentration in the plasma.
Similar down-regulation of NKCC1 has been observed in cells from healthy and depressed pregnant women [28] and T1D patients [7] . This observation thus indicates a general shift of immune regulation by altered GABA signaling, rather than a decrease specifically associated with depression. Another possibility is that reduced expression of NKCC1 is a trait conferring vulnerability for depression.
This study has several limitations. First, the patients were recruited in a naturalistic setting and have different combinations of medications that may influence GABA signaling. The careful selection of patients has, however, reduced the effects of other confounders, such as alcohol use and recent electroconvulsive therapy. Secondly, patients with depression are in different stages of the disease process. Thirdly, as this is a pilot study, we have not done correction for multiple testing and the findings must be validated in new cohorts. Finally, here the control blood was obtained from the hospital blood-central facility and donors were only matched for sex and age and were not evaluated in terms of mental health. A strength of this study is the inclusion of patients with severe depressive states which increases the likelihood that these results are relevant for a clinical psychiatric population.
The study shows that significant changes take place in the immune system during depression andidentifies molecules and mechanism important for immunomodulation in depression.
( Fig. 5 ). Levels of several inflammatory molecules including NGFs, IL-18 and CST5 were altered in plasma of patients with depression. In PBMCs from the patients GABA modulated release of cytokines. The average GABA level in the plasma from patients was increased whereas the NKCC1 expression in the PBMCs was decreased. Together the results suggest altered GABA signaling during depression. Future studies are required to understand if specific subpopulations of immune cells are involved in mental illness and then, how they are regulated. Further, the link between concentrations of small molecules like GABA, NGFs and CST5 in plasma and brain functions needs to be explored.
Materials and Methods

Study individuals, ethical permits and blood samples
Psychiatric illness was diagnosed using the International Neuropsychiatric Interview (M.I.N.I.
6.0) and the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria. The
interviews were conducted by two resident physicians in psychiatry and a specialized nurse in psychiatry at the clinic [70] . Patients were recruited at the Department of General Psychiatry at Uppsala University Hospital, Sweden, and the inclusion criteria for this study was that they met the DSM IV criteria for current moderate to severe depressive episode and either major depressive disorder or bipolar disorder at the time of blood sample collection. Depression severity was assessed using the self-rating version of Montgomery Åsberg depression rating scale (MADRS) [71, 72] . It is a 10-item clinician-rated scale measuring severity of depressive symptoms including the following items: reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimism and suicidal thoughts. The items are rated on a Likert scale from 0 to 6 and the total score ranges from 0 to 60. Higher scores indicate a greater severity. The study was approved by the Regional Ethics Committee in Uppsala (D.nr 2014/148 2014-06-12 and 2015-11-02), and all participants provided written consent. Twenty-five psychiatric patients with a major depressive episode participated in the study. Venous blood samples from the patients (P) were collected in EDTA tubes and used to isolate plasma and PBMCs. Twenty-six control blood samples from blood donors (CBD) were obtained at the blood center at Uppsala University Hospital.
Plasma and PBMC isolation from blood samples
Plasma and PBMCs were isolated from freshly drawn derived blood samples as previously described [28] . The plasma was isolated by centrifugation at 3,600 rpm for 10 min at 4 °C and immediately frozen at -80 °C. PBMCs were prepared by first diluting the blood samples in equal volume of MACS buffer (Miltenyi Biotec, Madrid, Spain), and layered on Ficollpaque plus (Sigma-Aldrich, Hamburg, Germany). Briefly, the samples were then subjected to density gradient centrifugation at 400 g for 30 min at room temperature. The PBMCs were carefully withdrawn and washed twice in MACS buffer. A portion of purified PBMCs was saved in RNAlater (Sigma-Aldrich) at -80 °C for mRNA extraction for qPCR experiments, and the remaining portion was used for analysis of cell culture supernatants by multiplex proximity extension assay (PEA).
Multiplex PEA for inflammatory marker measurements
Plasma samples, and culture media supernatants were analyzed using multiplex PEA with a panel of 92 inflammation-related proteins (multiplex Inflammation I 96×96 , Olink Proteomics TM , Uppsala, Sweden) as previously described [73] . In brief, 1 µl of sample or negative control was incubated overnight at 4 °C with a panel of oligonucleotides-conjugated antibodies, where each target protein can be recognized by a pair of antibodies. This binding brings the attached oligonucleotides in close proximity, allowing them to hybridize to each other and subsequently extended via enzymatic DNA polymerization, creating DNA amplicons, which are quantified using microfluidic-based quantitative real-time PCR system (Fluidigm, San Francisco, CA, USA). To even out intra-plate variations, the raw quantification cycle (Cq) values were normalized against spiked-in controls and negative controls to achieve normalized protein expression (NPX) values. NPX is an arbitrary value in log 2 scale, where an increase of a unit corresponds to a two-fold increase of protein concentration. These NPX data were then converted to linear data, using the formula 2 NPX , prior to further statistical analysis. Each protein has its own limit of detection (LOD) defined as the NPX of background plus three times standard deviations. The multiplex PEA is reported to have a sensitivity in subpicomolar and a broad dynamic range. The technical performances including LOD, dynamic range, etc., for all the proteins included in the panel is available at the manufacturer's homepage: https://www.olink.com/data-you-cantrust/publications. Proteins with levels below LOD were excluded from further data analysis.
Determination of GABA concentration
Plasma samples were thawed and the levels of GABA were measured using an ELISA kit (LDN Labor Diagnostika Nord, Nordhorn, Germany) as per manufacturer's guidelines [69] .
In brief, plasma samples and standards provided in the kit were extracted on extraction plate, derivatized using equalizing reagent and subjected standard competitive ELISA in GABA coated microtiter strips. The absorbance of the solution in the wells was read at 450 nm within 10 min using Multiskan MS plate reader (Labsystems, Vantaa, Finland). Optical density was used to calculate the GABA concentration using a standard curve.
Real-Time Quantitative Reverse Transcription PCR
The PBMC samples collected from 26 CBD and 25 patients were subjected to total mRNA extraction using RNA/DNA/Protein Purification Plus Kit (Norgen Biotek, Ontario, Canada).
RNA concentration was measured using Nanodrop (Nanodrop Technologies, Thermo Scientific, Inc., Wilmington, DE, USA). Further, 1.5 μg RNA was treated with 0.6 U DNAase I (Roche, Basel, Switzerland) for 30 min at 37 o C, with 8 mM EDTA for 10 min at 75 o C and then converted to cDNA using Superscript IV reverse transcriptase (Invitrogen, Stockholm, Sweden) in a 20 μl reaction. Reverse transcriptase negative reaction was also carried out in order to confirm the absence of genomic DNA contamination. The gene-specific primer pairs are listed in Table S1 . The PCR amplification was performed using the ABI PRISM 7900 HT Sequence Detection System (Applied Biosystems) with an initial denaturation step of 5 min at 95 °C, followed by 45 cycles of 95 °C for 15 s, 60 °C for 30 s and 72 °C for 1 min.
PBMC supernatants for multiplex PEA
The cells were suspended in complete medium (RPMI 1640 supplemented with 2 mM glutamine, 25 mM HEPES, 10% heat inactivated fetal bovine serum, 100 U/ml penicillin, 10 mg/ml streptomycin, 5 M β-mercaptoethanol) in a concentration of 1 million cells per ml.
The cells (100 µl = 100000 cells) were added in triplicate for each experimental group to the 96-well plates pre-coated with 3 μg/ml anti-CD3 antibody (clone HIT3a, BD Biosciences) for 3-5 h at 37 °C. The cells were then incubated in presence or absence of GABA at the relevant concentration for 72 h at 37 °C (95% O 2 , 5% CO 2 ) and supernatant culture media were collected, centrifuged to remove cellular debris and stored at -80 °C for the analysis of inflammatory markers using the multiplex PEA as mentioned above.
Statistical Analysis
Statistical analysis and data mining were performed using Statistica 12 (StatSoft Scandinavia, Uppsala, Sweden) and GraphPad Prism 7 (La Jolla, CA, USA). The statistical tests were performed after omitting outliers identified by the Tukey test. The differences between groups were assessed by nonparametric Kruskal-Wallis ANOVA on ranks with Dunn's post hoc test. The contingency of sex equality between the two groups was accessed by Fisher's exact test and age was accessed by non-parametric Mann-Whitney test. The correlation between inflammatory markers and demographic factors was accessed using nonparametric Spearman rank correlation. To reduce the risk of false discoveries caused by multiple testing, the Benjamini-Hochberg false discovery rate method was used [74] . The significance level was set to p < 0.05.
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Figure 2. Inflammatory markers correlation with age and GABA in control blood donors and patients.
Correlation between inflammatory marker levels in plasma samples and age of (A) control blood donors and (B) patients. Only inflammatory markers with significant correlation are shown. (C) Classification based on the cellular functions of markers that were significantly correlated with age of control blood donors (10 inflammatory markers) and patients (21 inflammatory markers). (D) Quantification of GABA levels in plasma samples from control blood donors and patients. (E) Correlation between inflammatory marker levels and GABA levels in plasma samples control blood donors. (F) Correlation between inflammatory marker levels and MADRS score in plasma samples control blood donors. The correlation between inflammatory markers and demographic factors was accessed using non-parametric Spearman rank correlation. To reduce the risk of false discoveries caused by multiple testing, the Benjamini-Hochberg false discovery rate method was used. Rho values and p values of correlation statistics are provided in Table S5 . * p < 0.05, ** p < 0.01, *** p < 0.001. (Table S8 ). ** p < 0.01. (Table S3 ) in PBMCs media from patients by Proseek Multiplex PEA inflammation panel I revealed expression of 59 (light red) and 68 (blue) inflammatory markers from non-stimulated and anti-CD3 stimulated PBMCs, respectively (Table S6 ). Data is represented by 2 NPX values as floating bars (minimum to maximum) arranged in descending order of mean expression level of the inflammatory markers. (B-C) Expression of inflammatory markers that are significantly affected by (B) GABA 100 nM and (C) GABA 500 nM treatment of anti-CD3 stimulated PBMCs from patients. Data is represented by 2 NPX values normalized to controls as a bar graph with mean ± SEM. Mean values with SEM and p values are provided in Table S7 . The differences between groups were assessed by nonparametric Kruskal-Wallis ANOVA on ranks with Dunn's post hoc test (Table S7) . p < 0.05 for (B) and (C).
Figure 5. Inflammatory markers in plasma or released from stimulated PBMCs in vitro.
Dark blue circle: Inflammatory markers detected in supernatants from anti-CD3 antibody stimulated PBMCs from patients. Light blue circle: Inflammatory markers detected in plasma samples from control blood donors (CBD) and patients (P). Violet circle: Inflammatory markers regulated by GABA in PBMCs from (P). Red circle: Inflammatory markers altered in plasma of (P) compared to (CBD). Blue: Inflammatory markers that correlated with age in only (P), green: Inflammatory markers that correlated with age in only (CBD), brown: Inflammatory markers that correlated with age in both (P) and (CBD), violet: Inflammatory markers that correlated with GABA concentration in blood from (CBD). 
Medication n (% of total)
Other anxiolytic medications** 11(44%) Antidepressive treatment*** 21(84%) Antipsychotics 6(24%) Benzodiazepines (A) 5 (20%) Z-analogues (B) 6 (24%) *One case of Asperger's and dyslexia, one case of ADHD, one case presented psychotic symptoms, and one patient has since this study committed suicide. ** Sedating antihistamines, phenothiazines. ***SSRI, SNRI, mood stabilizers and atypical antidepressants. The contingency of sex equality between the two groups was accessed by Fisher's exact test (p = 0.99) and age was accessed by non-parametric Mann-Whitney test (p = 0.61). The p values for the spearman correlation before and after the Bejamini and Hochberg correction procedure for false discovery rate of 5% are indicated as p value and adjusted p value, respectively. 
